임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-14 01:01
논문번호 109
논문제목(영문) Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Lee MG
교신저자명 Jeong MH
공동저자명 Lee MG, Jeong MH, Ahn Y, Cho JG, Park JC, Kang JC, Chae SC, Hur SH, Hong TJ, Kim YJ, Seong IW, Chae JK, Rhew JY, Chae IH, Cho MC, Bae JH, Rha SW, Kim CJ, Choi D, Jang YS, Yoon J, Chung WS, Seung KB, Park SJ;
게제년월일 2011-05-10
ISSN 1346-9843
Impact Factor 3.940
학술지명 Circulation journal
서지사항 0집 / 75권 / 9호,   페이지(2120 - 2127)
요약초록문
(Abstract) 입력		 BACKGROUND: The purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (PES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent (ZES) in primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with metabolic syndrome (MS).
METHODS AND RESULTS: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005-December 2007), a total of 1,768 MS patients with STEMI who underwent primary PCI were enrolled: The PES group was 634, SES group, 906, and ZES group, 228. The primary endpoint was major adverse cardiac event (all-cause death, re-myocardial infarction, target lesion revascularization) during 12 months follow-up. At 12 months, the cumulative incidence of primary endpoint in the PES, SES, and ZES groups was 10.9%, 9.1%, and 11.0%, respectively (P=0.086). Incidence of death, recurrent myocardial infarction, or target lesion revascularization did not differ among the 3 groups. There were 7 episodes of acute (0.3% in PES group, 0.4% in SES group, and 0.4% in ZES group, respectively, P=0.773) and 18 episodes of cumulative stent thrombosis including late stent thrombosis (0.9% in PES group, 1.0% in SES group, and 1.3% in ZES group, respectively, P=0.448).
CONCLUSIONS: Implantation of SES, PES, and ZES in MS patients with STEMI
파일  C109.+Circ+J.+2011;75(9)2120-2127..pdf (1.3M) DATE : 2021-05-25 14:32:44